Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Biomaterials
- Vol. 270, 120685
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea
This publication has 58 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Binding and uptake of H-ferritin are mediated by human transferrin receptor-1Proceedings of the National Academy of Sciences, 2010
- Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanomaCancer, 2010
- Self-assembling chimeric polypeptide–doxorubicin conjugate nanoparticles that abolish tumours after a single injectionNature Materials, 2009
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007
- Biological Containers: Protein Cages as Multifunctional NanoplatformsAdvanced Materials, 2007
- Magnetic Resonance Visualization of Tumor Angiogenesis by Targeting Neural Cell Adhesion Molecules with the Highly Sensitive Gadolinium-Loaded Apoferritin ProbeCancer Research, 2006
- Viruses: Making Friends with Old FoesScience, 2006
- PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesisClinical Immunology, 2005